Skip to main navigation menu Skip to main content Skip to site footer
×
Español (España) | English
Editorial
Home
Indexing
Original

Evaluating the immunogenic potential of bax protein isoforms as therapeutic targets in oncology: brief report

By
Luis Fabián Salazar-Garcés ,
Luis Fabián Salazar-Garcés

Faculty of Health Sciences, Technical University of Ambato, Ecuador

Search this author on:

PubMed | Google Scholar
Diana Catalina Velastegui-Hernandez ,
Diana Catalina Velastegui-Hernandez

Faculty of Health Sciences, Technical University of Ambato, Ecuador

Search this author on:

PubMed | Google Scholar
Lizette Elena Leiva Suero ,
Lizette Elena Leiva Suero

Faculty of Health Sciences, Technical University of Ambato, Ecuador

Search this author on:

PubMed | Google Scholar

Abstract

Through a methodical approach that combines bioinformatics and immunological analysis, detailed genetic sequencing and structural analysis of seven BAX isoforms were conducted. Using databases such as NCBI and Uniprot, and algorithms for sequence alignment and structural predictions, promising features in specific isoforms were identified. Tools like BCPREDS and the Immune Epitope Database helped evaluate the immunogenic potential by mapping epitopes.
The results highlighted that isoforms such as BAX-alpha and BAX-gamma have high immunogenic capacities, making them candidates for the development of targeted vaccines or as direct therapeutic agents. Structural analyses suggested that some isoforms have the capability to integrate into cell membranes and alter signaling pathways, inducing apoptosis selectively in cancer cells.
In summary, this study underscores the importance of BAX isoforms in the evolution of cancer therapy, offering more specific treatment approaches with lower toxicity. These findings encourage a move towards precision medicine in oncology, personalizing treatments based on molecular and genetic profiles to optimize therapeutic efficacy and reduce adverse effects, promising to improve outcomes for patients.

How to Cite

1.
Salazar-Garcés LF, Velastegui-Hernandez DC, Leiva Suero LE. Evaluating the immunogenic potential of bax protein isoforms as therapeutic targets in oncology: brief report. Salud, Ciencia y Tecnología - Serie de Conferencias [Internet]. 2023 Dec. 23 [cited 2024 Jun. 29];2:587. Available from: https://conferencias.saludcyt.ar/index.php/sctconf/article/view/587

The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.

Article metrics

Google scholar: See link

Metrics

Metrics Loading ...

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.